BIOGEN INC. News
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
see moreBIOGEN INC. Market News
6d
Biogen's Diranersen Shows Promise in Alzheimer's Treatment, Stock Reacts
- Biogen's diranersen shows promise in Alzheimer's treatment, stock reacts.
13d
Biogen's Strategic Moves and Analyst Reactions Shape Stock Performance
Biogen's recent acquisitions and FDA designations influence stock trends.
18d
Biogen's Stock Decline Amidst Recent Developments in Alzheimer's Treatment
Biogen's stock dips following mixed results in Alzheimer's drug trials.
26 Mar at 00:40
Biogen Surges After EU Spinraza Nod, Insider Gains
Biogen (BIIB) saw share strength after the EU approved a high-dose Spinraza formulation and investor attention rose following a disclosed congressional stock purchase that has since appreciated substantially. These concrete developments improve near-term commercial prospects and have driven sentiment around BIIB.
05 Mar at 00:37
Biogen Rally: Earnings Beat, Barclays Initiates Q1
Biogen shares recently rose after better-than-expected FY2025 results and upbeat profit metrics, while Barclays started coverage with an Equal-Weight rating. Near-term FDA PDUFA dates for Leqembi (May 24) and SPINRAZA (April 3) and late-stage pipeline readouts make BIIB a catalyst-driven story.
26 Feb at 00:36
Biogen Beat-and-Raise: Spinraza, Leqembi Catalysts
Biogen’s recent beat-and-raise positions the company for a catalyst-rich H1 2026. Key near-term events — Spinraza PDUFA (Apr 3), Parkinson’s LUMA data (Mar), and a subcutaneous Leqembi decision (May 24) — could materially affect BIIB’s trajectory and investor sentiment.
19 Feb at 00:38
Biogen Rally: Leqembi FDA Review Boosts BIIB Surge
Biogen (BIIB) surged after a Q4 beat, raised guidance and the FDA accepted a priority filing for a subcutaneous Leqembi formulation with a May 24 PDUFA date. Combined with leadership changes and expanded SPINRAZA approval in Europe, these concrete catalysts are reshaping investor sentiment and could influence liquidity and index relevance.